Premium
Prognostic significance of p‐STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy
Author(s) -
Choi Chel Hun,
Song Sang Yong,
Kang Heeseok,
Lee YooYoung,
Kim ChulJung,
Lee JeongWon,
Kim TaeJoong,
Kim ByoungGie,
Lee JeHo,
Bae DukSoo
Publication year - 2010
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2009.01131.x
Subject(s) - medicine , chemotherapy , immunohistochemistry , oncology , pathological , cervical cancer , cervical carcinoma , biopsy , neoadjuvant therapy , carcinoma , cancer , breast cancer
Aim: To better predict treatment responses for managing bulky cervical carcinoma with neoadjuvant chemotherapy (NAC). Methods: The expression of p‐STAT3 was analyzed by immunohistochemistry using paraffin‐embedded pretreatment cervical biopsy tissues. The study included 29 patients with bulky IB to IIA cervical squamous cell carcinoma treated with NAC. Results: Twenty (69.0%) of 29 patients were scored as p‐STAT3‐positive. Pathological response to chemotherapy (complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight patients (27.6%). The p‐STAT3‐positive patients had a longer disease‐free survival compared to p‐STAT3‐negative patients ( P = 0.03), though they had more frequent clinical nodal involvement ( P = 0.046). Conclusion: Pretreatment assessment of p‐STAT3 expression may provide additional information for the identification of patients with cervical cancer who have a favorable prognosis.